The changing pattern of adenocarcinoma of the EGJ
P.I. Reed (Slough) 

The epidemiology of adenocarcinoma of the esophagus and gastric cardia in the North West of England
J.P. Byrne (Dublin), J.M. Parry, C.B.J. Woodman, S.E.A. Attwood (Salford) 

What is the role of dietary intake in their development?
L.H. Bernstein, A. Wu (Los Angeles) 

Is the increasing use of drug therapy for reflux esophagitis a possible cause of sustained mitotic stimulation, eventually promoting esophageal carcinogenesis?
G. Willems, A. De Backer, 0. Peeters, Y. Van Nieuwenhove (Brussels) 

Is it possible to evaluate the rate of late-developed adenocarcinomas on Barrett's esophagus after successful AR repair?
F. Johnsson (Lund) 

Do all adenocarcinomas at or near the EGJ have the same epidemiologic characteristics?
H.D. Appelman (Ann Arbor) 

Could the rising frequency of cancer at the EGJ be related to undetected short-segment Barrett's esophagus?
S.J. Spechler (Dallas) 

What are the experimental data on the relationship between gastric or duodenal reflux and esophageal adenocarcinomas?
S.E.A. Attwood (Salford), J.P. Byrne (Dublin) 

How should the increasing incidence of adenocarcinomas of EGJ compared to cardia adenocarcinoma be interpreted?
G.R. Locke III (Rochester, MN) 

Pathology

Are there minimal criteria for the confident or unequivocal diagnosis of invasive carcinoma in the lamina propria both in Barrett's mucosa and in squamous mucosa?
H.D. Appelman (Ann Arbor) 
R.H. Riddell (Hamilton) 

Can adenocarcinomas of the cardia and short segment of Barrett's mucosa be differentiated morphologically?
H.D. Appelman (Ann Arbor) 

Is mediastinal lymph node involvement to be considered as a stage IV disease?
T. Lerut (Leuven) 

Are all carcinomas arising immediately above, immediately below and within the gastroesophageal junction region the same?
R.A. Hinder (Jacksonville), N. Katada, R.J. Lund, G. Perdikis, C.J. Filipi (Omaha) 

Is there a difference in prognosis between carcinoma of the cardia and Barrett's carcinoma?
J. Johansson (Lund) 

Has a metaplasia dysplasia-carcinoma sequence been identified for carcinoma of the cardia?
S.R. Hamilton (Baltimore) 

Is there evidence of a common cell type of origin for adenocarcinomas arising in Barrett's esophagus and the gastric cardia?
R.S.J. Thomas (Melbourne) 

What is the role of suppression of the T-lymphocyte function?
G.C. O'Sullivan, M.G. O'Brien, J. O'Connell, J.K. Collins, F. Shanahan (Cork) 

Endoscopic treatments

How may EUS influence the therapeutic approach?
Y. Murata, S. Suzuki, H. Ogma, Y. Kitamura, H. Ide, H. Suzuki (Tokyo) 

Is endoesophageal MRI likely to improve staging of adenocarcinomas at the EGJ?
H. van Overhagen, J. Stoker (Rotterdam) 

Is there a place for endoscopic mucosectomy in early cancers of the cardia or EGJ?
T. Kawano, M. Endo (Tokyo) 

What are the indications and results of endoscopic resection of early esophageal cancer?
M. Endo, T. Kawano, H. Inoue (Tokyo) 

In cases of endoscopic mucosal resection, should EUS evaluation by a miniature probe be recommended to make the indication more accurate?
T. Kawano, M. Endo (Tokyo) 

When is photodynamic therapy indicated for adenocarcinomas on Barrett's esophagus?
P. Spinelli, M. Dal Fante, A. Mancini (Milan) 

Is laser application likely to be improved by the use of novel devices?
E.J. Fricker (Sayre) 

Surgical treatments

What is the value of preoperative laparoscopy in the management of adenocarcinoma of the cardia?
L. Bonavina, R. Incarbone, A. Peracchia (Milan) 

Should histological differentiation induce specific modifications in the resection of adenocarcinomas of the GEJ?
J. Fass, B. Dreuw, K. Ophoff, V. Schumpelick (Aachen) 

What should be the extent of esophageal and gastric resection?
M. Endo (Tokyo) 

Is there any anatomic justification for partial esophagectomy in cancer of the cardia?
R. Sarrazin (Grenoble) 

The left thoracoabdominal approach for adenocarcinoma of the EGJ
T.H. Gouge (New York) 

The endoesophageal pull-through
F. Saidi (Tehran) 

When could bilateral thoracotomy be envisaged in lower esophageal cancer?
K. Iwase, W. Kamiike, T. Kido, T. Takao, H. Matsuda (Osaka) 

Multimodality treatments

What can be expected from a multimodality approach to adenocarcinomas of the esophagus?
D.P. Kelsen (New York) 

What is currently the most efficient combination chemotherapy?
J. Rouëssé, F. Cvitkovic (Saint-Cloud) 

Are adenocarcinomas of the cardia resistant, as gastric cancers, to quinone anti-cancer drugs and radiation therapy?
R. Izutani, S. Asano, M. Imano, M. Kato, H. Ohyanagi (Osaka), J. Chihara (Akita) 

What is the updated evaluation of the results of radiotherapy or brachytherapy in adenocarcinomas of the EGJ? How can the tumor response after irradiation be evaluated?
B.G. Taal, B.M.P. Aleman, H. Boot (Amsterdam) 

What benefit can be expected from brachytherapy in adenocarcinomas of the EGJ?
B.G. Taal (Amsterdam) 

What is the future prospect of gene therapy utilising p53?
D.S. Schrump, J.A. Roth (Houston) 

Is there a correlation between specific non molecular morphologic features of Barrett's carcinoma and prognosis?
K. Geboes, N. Ectors (Leuven) 

Is the expression of c-erb B-2 oncogene protein in tumor cells of independent prognostic importance in Barrett's carcinoma?
J.F. Fléjou (Paris)